Format

Send to

Choose Destination
Can Urol Assoc J. 2017 Mar-Apr;11(3-4):E138-E142. doi: 10.5489/cuaj.4371. Epub 2017 Apr 11.

Systematic review of the potential role of cannabinoids as antiproliferative agents for urological cancers.

Author information

1
Michael DeGroote School of Medicine, St Joseph's Hospital; Hamilton, ON, Canada.
2
McMaster Institute of Urology, St Joseph's Hospital; Hamilton, ON, Canada.

Abstract

INTRODUCTION:

The palliative effects of cannabis sativa (marijuana), which include appetite stimulation, attenuation of nausea and emesis, and pain relief, are well known. The active components of cannabis sativa (cannabinoids) and their derivatives have received growing interest due to their diverse pharmacological activities, such as cell growth inhibition and tumour regression. The aim of this review is to look at the current evidence on the antiproliferative effects of cannabinoids in urological malignancies, including renal, prostate, bladder, and testicular cancers.

METHODS:

We conducted a systematic review of studies exploring the effect of cannabinoids on tumour activity, including all study types except expert opinions. A formal search was run on Medline database from 1946 to September 2016, along with a hand-search on PubMed for relevant studies.

RESULTS:

The search yielded a total of 93 studies from Medline and PubMed, of which 23 studies were included in the final analysis. To date, there are various in vitro studies elucidating the potential mechanism of action of cannabinoids for urological cancers, along with population-based studies specifically for testicular malignancies. To date, no clinical trials have been conducted for urological cancer patients.

CONCLUSIONS:

These results demonstrate that the role of endocannabinoids for urological malignancies is an area of active research. Further research is required not only to evaluate the crosstalk between cancer signaling pathways and cannabinoids, but also large randomized clinical studies with urological patients need to be conducted before cannabinoids can be introduced as potential therapeutic options for urological neoplasms.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center